lncRNA LUNAR1 accelerates colorectal cancer progression by targeting the miR‑495‑3p/MYCBP axis
- Jiajie Qian
- Alok Garg
- Fuqiang Li
- Qianyun Shen
- Ke Xiao
Affiliations: Department of Gastrointestinal Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, Department of Surgery, City Hospital Braunschweig, D‑38118 Braunschweig, Germany, Department of Thyroid Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, D‑30625 Hannover, Lower Saxony, Germany
- Published online on: September 25, 2020 https://doi.org/10.3892/ijo.2020.5128
Copyright: © Qian
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Colorectal cancer (CRC) is a tumor type characterized by high patient morbidity and mortality. It has been reported that long non‑coding (lncRNA) LUNAR1 (LUNAR1) participates in the regulation of tumor progression, such as diffuse large B‑cell lymphoma. However, its role and underlying mechanisms in CRC progression have not been elucidated. The present study was designed to investigate the underlying mechanisms by which LUNAR1 regulates CRC progression. RT‑qPCR and Pearson's correlation analysis revealed that LUNAR1 was highly expressed and was negatively associated with the overall survival of CRC patients. Moreover, CCK‑8, clone formation, wound‑healing migration, Transwell chamber and FACs assay analyses showed that LUNAR1 knockdown inhibited CRC cell proliferation, migration and invasion, while accelerating cell apoptosis. Additionally, LUNAR1 was found to function as a sponge of miR‑495‑3p, which was predicted by TargetScan and confirmed by luciferase reporter assay. Furthermore, functional studies indicated that miR‑495‑3p overexpression inhibited CRC cell proliferation, migration and invasion, while accelerating cell apoptosis. In addition, bioinformatics and luciferase reporter assays showed that miR‑495‑3p was found to negatively target Myc binding protein (MYCBP), and functional research showed that LUNAR1 accelerated CRC progression via the miR‑495‑3p/MYCBP axis. In conclusion, LUNAR1 accelerates CRC progression via the miR‑495‑3p/MYCBP axis, indicating that LUNAR1 may serve as a prognostic biomarker for CRC patients.